• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The initial timing and dosage pattern of sacubitril/valsartan in patients with acute myocardial infarction undergoing percutaneous coronary intervention
CONCLUSIONS: Early use or high dosage of sacubitril/valsartan medication is associated with an improvement in clinical outcome. The low dose of sacubitril/valsartan is well tolerated and may be an acceptable alternative strategy.PMID:36990878 | DOI:10.1016/j.ejim.2023.03.019
Source: European Journal of Internal Medicine - March 29, 2023 Category: Internal Medicine Authors: Jun Gu Yue Wang Chang-Qian Wang Jun-Feng Zhang Source Type: research

Left ventricular output indices and sacubitril/valsartan titration: role of stroke volume index
ConclusionsStroke volume index is positively associated with complete titration of sacubitril/valsartan. Patients with low SVi are more prone to experience hypotension during titration
Source: ESC Heart Failure - March 23, 2022 Category: Cardiology Authors: Paolo Tolomeo, Ottavio Zucchetti, Emanuele D'Aniello, Noemi Punzo, Federico Marchini, Luca Di Ienno, Elisabetta Tonet, Rita Pavasini, Claudio Rapezzi, Gianluca Campo, Matteo Serenelli Tags: Short Communication Source Type: research

Sacubitril/Valsartan Improves Left Atrial and Left Atrial Appendage Function in Patients With Atrial Fibrillation and in Pressure Overload-Induced Mice
LCZ696 (sacubitril/valsartan) is an angiotensin receptor-neprilysin inhibitor and has shown beneficial effects in patients with heart failure. However, whether LCZ696 protects against left atrial (LA) and LA appendage (LAA) dysfunction is still unclear. The present study aimed to assess the efficacy of LCZ696 for improving the function of LA and LAA. We performed both a retrospective study comparing LCZ696 with angiotensin receptor blockers (ARBs) to assess the efficacy of LCZ696 in patients with atrial fibrillation and an animal study in a mouse model with pressure overload. LA peak systolic strain, LAA emptying flow velo...
Source: Frontiers in Pharmacology - October 28, 2019 Category: Drugs & Pharmacology Source Type: research

Effectiveness and safety of valsartan/amlodipine in hypertensive patients with stroke: China Status II subanalysis
Abstract: High blood pressure (BP) is a major risk factor associated with stroke in China. This is a subanalysis of patients from the China Status II study, aimed to evaluate the effectiveness and safety of valsartan/amlodipine (Val/Aml) single-pill combination (SPC) in hypertensive patients with different stroke subtypes (hemorrhagic, ischemic, or mixed). China Status II was a multicenter, postmarketing, prospective observational study in hypertensive patients uncontrolled on monotherapy. The study was an 8-week open-label treatment period with 2 4-week follow-ups. Change in BP from baseline to weeks 4 and 8, BP control ...
Source: Medicine - June 1, 2017 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Pre-treatment with LCZ696, an orally active angiotensin receptor neprilysin inhibitor, prevents ischemic brain damage.
Abstract Angiotensin II receptor blockers (ARBs) are known to prevent ischemic brain damage after stroke. Natriuretic peptides, which are increased by a neprilysin inhibitor, are also reported to protect against brain damage. Therefore, we investigated the possible protective effect of valsartan (VAL) compared with LCZ696 (VAL+ neprilysin inhibitor; 1:1) after middle cerebral artery (MCA) occlusion. Eight-week-old male C57BL/6J mice were treated with VAL (3mg/kg per day) or LCZ696 (6mg/kg per day) for 2 weeks before MCA occlusion. Blood pressure and heart rate were measured by telemetry. Cerebral blood flow (CBF) ...
Source: European Journal of Pharmacology - June 6, 2015 Category: Drugs & Pharmacology Authors: Bai HY, Mogi M, Nakaoka H, Kan-No H, Tsukuda K, Chisaka T, Wang XL, Kukida M, Shan BS, Yamauchi T, Higaki A, Iwanami J, Horiuchi M Tags: Eur J Pharmacol Source Type: research

Modest blood pressure reduction with valsartan in acute ischemic stroke: a prospective, randomized, open‐label, blinded–end‐point trial
ConclusionsEarly reduction of BP with valsartan did not reduce death or dependency and major vascular events at 90 days, but increased the risk of END.
Source: International Journal of Stroke - January 12, 2015 Category: Neurology Authors: Mi Sun Oh, Kyung‐Ho Yu, Keun‐Sik Hong, Dong‐Wha Kang, Jong‐Moo Park, Hee‐Joon Bae, Jaseong Koo, Juneyoung Lee, Byung‐Chul Lee, Tags: Research Source Type: research

Walking reduces heart disease in people at risk
Conclusion This study of adults at high risk of type 2 diabetes and heart disease has found that every 2,000 steps they normally took each day was associated with a 10% lower risk of a cardiovascular event. And 12 months later, each extra 2,000 steps per day people did beyond their original number of steps was associated with an additional 8% difference in the cardiovascular event rate. This large study recruited participants from around the world and the researchers adjusted for a number of potential confounders. However, the study had a number of limitations, including: A large amount of information on the number of s...
Source: NHS News Feed - December 23, 2013 Category: Consumer Health News Tags: Lifestyle/exercise Source Type: news